Explore the results of a Phase 1 dose escalation trial on the sequential combination of ropeginterferon alfa-2b and anti-PD-1 therapy as adjuvant treatment in HBV-related hepatocellular carcinoma (HCC). This study offers valuable insights into the safety and potential efficacy of novel immunomodulatory strategies in post-operative settings.

Read the full article here: https://link.springer.com/article/10.1007/s12072-025-10824-4